Showing 4141-4150 of 10903 results for "".
- Marie Claire Recognizes ZORYVE for Atopic Dermatitis Treatmenthttps://practicaldermatology.com/news/marie-claire-recognizes-zoryve-for-atopic-dermatitis-treatment/2488632/Arcutis Biotherapeutics announced that roflumilast cream 0.15% (ZORYVE) received Marie Claire’s inaugural 2026 Best Prescription Skin Solution Award, a new category recognizing innovation in prescription dermatologic treatments. The award recognizes ZORYVE f
- World Chronic Hand Eczema Day to Launch October 5https://practicaldermatology.com/news/world-chronic-hand-eczema-day-to-launch-october-5/2488610/The first World Chronic Hand Eczema Day will take place October 5, 2026, bringing patients, clinicians, and advocacy organizations together to increase awareness of chronic hand eczema (CHE) and its effects beyond the skin, according to a press release. Hand eczema i
- Phase 2 DLE Trial Meets Primary Endpoint With Daxdilimabhttps://practicaldermatology.com/news/eadv-phase-2-dle-trial-meets-primary-endpoint-with-daxdilimab/2488598/Daxdilimab improved measures of disease activity in adults with moderate-to-severe discoid lupus erythematosus (DLE), according to new data from a phase 2 trial presented at EADV 2026. Researchers included 72 adults aged 18 to 75 years with chronic, treatment-refrac
- Lebrikizumab Improves Hand and Foot AD in Phase 3b ADtouch Trialhttps://practicaldermatology.com/news/lebrikizumab-improves-hand-and-foot-ad-in-phase-3b-adtouch-trial/2488591/Lebrikizumab-lbkz (Ebglyss; Eli Lilly and Company) improved skin clearance, itch, and pain compared with placebo among adults and adolescents with moderate-to-severe atopic dermatitis (AD) affecting the hands and feet, according to Phase 3b ADtouch results presented at the
- New LATITUDE Data Detail Zasocitinib Efficacy, Durability in Plaque Psoriasishttps://practicaldermatology.com/news/new-latitude-data-detail-zasocitinib-efficacy-durability-in-plaque-psoriasis/2488590/New Phase 3 data presented at the European Academy of Dermatology & Venereology (EADV) Congress 2026 showed higher skin clearance rates with investigational oral tyrosine kinase 2 (TYK2) inhibitor zasocitinib (TAK-279) compared with deucravacitinib in adults with modera
- Incyte Previews Atopic Dermatitis, HS, Vitiligo Data for EADV 2026https://practicaldermatology.com/news/incyte-previews-atopic-dermatitis-hs-vitiligo-data-for-eadv-2026/2488546/Incyte will present new research spanning several immune-mediated skin diseases at the European Academy of Dermatology and Venereology (EADV) Congress 2026, scheduled for September 30 to October 3 in Vienna, Austria. Rather than focusing on a single disease or development program, the comp
- Expert Consensus Defines Best Practices for Pseudofolliculitis Barbaehttps://practicaldermatology.com/news/expert-consensus-defines-best-practices-for-pseudofolliculitis-barbae/2488539/A new expert consensus study published online in JAMA Dermatology outlines best practices for diagnosing and managing pseudofolliculitis barbae (PFB), including hair removal modification, medical therapy, procedural treatment, and occupational considerations.
- Dietary Allergens, Air Pollution, Humidity Linked to Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/dietary-allergens-air-pollution-humidity-linked-to-pediatric-atopic-dermatitis/2488526/Dietary allergen sensitization and environmental exposures were associated with pediatric atopic dermatitis (AD) in a 2-stage study published in Frontiers in Pediatrics.
- Risankizumab, Ustekinumab Linked to Lower Infection Risk in Psoriasishttps://practicaldermatology.com/news/risankizumab-ustekinumab-linked-to-lower-infection-risk-in-psoriasis/2488488/Biologics and small molecules used in psoriasis therapies had a favorable safety profile, according to new research in the Journal of Investigative Dermatology. Study researchers included 4,820 patients (8,826 treatment cycles; 20,829 patient years of follow-up) in the analysis.
- LEO Pharma Closes Dersimelagon Acquisition as FDA Accepts NDAhttps://practicaldermatology.com/news/leo-pharma-closes-dersimelagon-acquisition-as-fda-accepts-nda/2488489/LEO Pharma announced that the US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for dersimelagon for filing and granted Priority Review for the investigational treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The FDA has se